residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin the randomized diator trial残余β细胞功能在新诊断出患1型糖尿病与阿托伐他汀治疗后随机diator试验.pdfVIP

下载本文档

1
0
约5.77万字
约 8页
2017-09-11 发布于上海
举报
版权申诉

residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin the randomized diator trial残余β细胞功能在新诊断出患1型糖尿病与阿托伐他汀治疗后随机diator试验.pdf

1、本文档共8页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin the randomized diator trial残余β细胞功能在新诊断出患1型糖尿病与阿托伐他汀治疗后随机diator试验

Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after Treatment with Atorvastatin: The Randomized DIATOR Trial 1 ¤a 1 1,2 3 4 Stephan Martin * , Christian Herder , Nanette C. Schloot , Wolfgang Koenig , Tim Heise , Lutz Heinemann4, Hubert Kolb1¤b on behalf of the DIATOR Study Group ¨ 1 Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany, 2 Departments of ¨ Medicine and Metabolic Diseases, University Hospital, Dusseldorf, Germany, 3 Department of Internal Medicine II - Cardiology, University of Ulm Medical Center, Ulm, Germany, 4 Profil Institute for Metabolic Research, Neuss, Germany Abstract Background: Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent- onset type 1 diabetes. Methods and Findings: The randomised placebo-controlled Diabetes and Atorvastatin (DIATOR) Trial included 89 patients with newly diagnosed type 1 diabetes and islet autoantibodies (mean age 30 years, 40% females), in 12 centres in Germany. Patients received placebo or 80 mg/d atorvastatin for 18 months. As primary outcome stimulated serum C-peptide levels were determined 90 min after a standardized liquid mixed meal. An intent-to-treat analysis was performed. Fasting and stimulated C-peptide levels were not significantly dif